世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

歩行の凍結市場調査レポート:2030年までの予測


Freeze of Gait Market Research Report Forecast till 2030

歩行の凍結市場調査レポート:2030年までの予測 市場概要 歩行凍結市場は予測期間中に4.86%の複合年間成長率(CAGR)を示すと予測される。歩行凍結の普及が進んでいることが、市場拡大の重要な原動力の一つと... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Market Research Future
マーケットリサーチフューチャー (MRFR)
2023年11月15日 US$7,250
ライセンス・価格情報
注文方法はこちら
82 英語

 

サマリー

歩行の凍結市場調査レポート:2030年までの予測

市場概要
歩行凍結市場は予測期間中に4.86%の複合年間成長率(CAGR)を示すと予測される。歩行凍結の普及が進んでいることが、市場拡大の重要な原動力の一つとなっています。
パーキンソン病は、中枢触覚骨格の問題であり、固さや震え、協調性やバランス感覚の問題など、不注意や乱暴な方向転換を引き起こす。これらの後遺症は一般的に着実に始まり、長期的には一度消滅する。歩行や会話に支障をきたすこともある。歩行の凍結(霧)は、おそらくパーキンソン病(PD)患者の最も衰弱させる運動後遺症の一つである。歩行凍結は、予期せぬ歩行開始不能や歩行不能を引き起こす特異な歩行計画である。
ネイチャー・ジャーナル』誌に掲載されたデータによると、2022年にはパーキンソン病患者の約半数、最先端のパーキンソン病患者の80%が霧の影響を受けるという。パーキンソン財団によると、現在米国では約100万人がパーキンソン病(PD)と共に生活しており、2030年までにこの数は120万人に増加すると調査されている。
市場区分
歩行凍結市場は、脳深部刺激、ウェアラブル技術、歩行補助具、経口ドパミン薬、その他の製品がタイプ別に分類されている。
歩行凍結市場は、診療所、病院、その他の施設を含むエンドユーザーによって区分される。
地域別洞察
北米の歩行凍結市場は、2022年には4億8,000万米ドルに達し、レビュー期間中の年平均成長率は5.17%になると予測されています。これは、重要な参加者のビジネスプレゼンス、FDAのお墨付きの上昇、処方と治療法に関する意識の拡大、この地域におけるパーキンソン病の蔓延の高まりが、予測期間中の地域市場の発展を後押ししているためです。
欧州の歩行凍結市場は、医療利用の増加、最先端の治療薬への関心の高まり、老年人口の拡大が、パーキンソン病に関連する歩行凍結の賭けにつながり、欧州地域における歩行凍結の開発を促進するため、パイの2番目に大きな部分を占めると思われます。
病気発見のためのトレンド設定技術革新への開放性、歩行凍結に傾倒する老年人口の増加が、強力な治療と治療薬への関心を高め、歩行凍結に対する心構えを拡大させています。
アジア太平洋地域の歩行凍結市場は、2023年から2030年にかけて年平均成長率6.03%で発展すると考えられている。これは、臨床オフィスの増加、凍結歩行治療に対する政府の推進力の拡大、凍結歩行に関連するパーキンソン病の膨大な患者プールの存在などの要素が、アジア太平洋地域の凍結歩行市場の発展に大きく影響しているためです。その他の地域には、中東、アフリカ、ラテンアメリカが含まれます。
市場概要
歩行凍結市場の主要企業には、Teva Pharmaceuticals(イスラエル)、Sun Pharmaceutical Industries Ltd(インド)、Viatris Inc(米国)、Gondola Medical Technologies SA(スイス)、Gyenno Technologies Co.(中国)、Beats Medical Limited (アイルランド)、Agilitas (オーストラリア)、Walk with Path (Vesterbro)、MedEXO Robotics (香港)、Ustep (米国)。


ページTOPに戻る


目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF PARKINSON’S DISEASE AND OTHER RELATED DISEASES

4.2.2 GROWING GERIATRIC POPULATION

4.2.3 INCREASING INVESTMENT IN R&D

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY REQUIREMENTS

4.4 OPPORTUNITIES

4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS

5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS

5.3.4 IMPACT ON ELECTIVE PROCEDURE

5.3.5 IMPACT ON SUPPLY CHAIN

6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE

6.1 OVERVIEW

6.2 ORAL DOPAMINERGIC MEDICATION

6.3 WEARABLE AND WALKING AID DEVICES

6.4 DEEP BRAIN STIMULATION

6.5 OTHERS

7 GLOBAL FREEZE OF GAIT MARKET, BY END USER

7.1 OVERVIEW

7.2 HOSPITALS

7.3 CLINICS

7.4 OTHERS

8 GLOBAL FREEZE OF GAIT MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 US

8.1.2 CANADA

8.2 EUROPE

8.2.1 GERMANY

8.2.2 FRANCE

8.2.3 UK

8.2.4 ITALY

8.2.5 SPAIN

8.2.6 REST OF EUROPE

8.3 ASIA-PACIFIC

8.3.1 CHINA

8.3.2 INDIA

8.3.3 JAPAN

8.3.4 AUSTRALIA

8.3.5 SOUTH KOREA

8.3.6 REST OF ASIA-PACIFIC

8.4 REST OF THE WORLD

8.4.1 MIDDLE EAST

8.4.2 AFRICA

8.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET

9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.5.1 PARTNERSHIP & COLLABORATIONS

9.6 MAJOR PLAYERS SALES ANALYSIS

9.6.1 SALES & OPERATING INCOME

9.7 MAJOR PLAYERS R&D ANALYSIS

10 COMPANY PROFILES

10.1 VIATRIS INC.

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 GONDOLA MEDICAL TECHNOLOGIES SA

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 USTEP

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 GYENNO TECHNOLOGIES CO., LTD.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 MEDEXO ROBOTICS

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL ANALYSIS

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SUN PHARMACEUTICAL INDUSTRIES LTD

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 WALK WITH PATH

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 BEATS MEDICAL LIMITED

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 AGILITAS

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

ページTOPに戻る



図表リスト

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019–2030 (USD MILLION)

TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019–2030 (USD MILLION)

TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2030 (USD MILLION)

TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019–2030 (USD MILLION)

TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019–2030 (USD MILLION)

TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET

TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET

TABLE 65 PARTNERSHIP & COLLABORATIONS

TABLE 66 VIATRIS INC.: PRODUCTS OFFERED

TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED

TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS

TABLE 69 USTEP: PRODUCTS OFFERED

TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED

TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED

TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED

TABLE 74 WALK WITH PATH: PRODUCTS OFFERED

TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED

TABLE 76 AGILITAS: PRODUCTS OFFERED

 

ページTOPに戻る


 

Summary

Freeze of Gait Market Research Report Forecast till 2030

Market Overview
Freeze of Gait Market is projected exhibit a compound annual growth rate (CAGR) of 4.86% during the forecast period. The Rising transcendence of freeze of gait is one of the critical driving components for market advancement.
Parkinson's contamination is an issue of the central tactile framework that causes inadvertent or wild turns of events, like solidness, shaking, and issue with coordination and balance. These aftereffects generally begin steadily and annihilate once again the long run. This could achieve inconvenience walking and talking. Freezing of gait (Fog) is perhaps of the most debilitating motor aftereffect in Parkinson's affliction (PD) patients. Freezing of gait is a peculiar gait plan that prompts an unforeseen inability to begin or walk.
According to data appropriated in Nature Journal, in the year 2022, Fog affected around half of Parkinson's ailment patients and 80% of state-of-the-art Parkinson's disorder patients. According to the Parkinson's Foundation, at the present time around a million people in the US are living with Parkinson's disease (PD), and it is surveyed that this number will rise to 1.2 million by 2030.
Market Segmentation
Deep brain stimulation, wearable technology, walking aids, oral dopaminergic medications, and other products are included in the Freeze of Gait Market categorization based on type.
The Freeze of Gait Market is segmented according to end users, which encompasses clinics, hospitals, and other establishments.
Regional Insights
The North America Freeze of Gait market is supposed to represent USD 0.48 billion out of 2022 and is supposed to show a 5.17% CAGR during the review time frame. This is credited to the business presence of significant vital participant, rising FDA endorsement, and expanding mindfulness about the prescription and treatments, rising pervasiveness of Parkinson sickness in the region drive the regional market development during the forecast time frame.
Europe Freeze of Gait market is supposed to represent the second-biggest piece of the pie because of the rising medical care use, rising interest for cutting edge therapeutics, and expanding geriatric populace led to gamble of Parkinson illness related freeze of gait which drive the development of freeze gait in Europe region.
Openness to trend setting innovation for sickness finding, the rising geriatric populace inclined to Freeze of Gait is driving up interest for powerful therapy and therapeutics and expanding mindfulness about the freeze of gait.
The Asia-Pacific freeze of gait market is supposed to develop at a CAGR of 6.03% from 2023 to 2030. This is because of elements, for example, rising clinical office, expanding government drive for freeze gait treatment, presence of enormous patient pool of Parkinson illness related with freeze of gait are decidedly influence on the development of freeze of gait market in Asia-Pacific region. The Rest of the World incorporates the Middle East, Africa, and Latin America.
Market Overview
Key Companies in the Freeze of Gait Market Include Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), and Ustep (US).



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF PARKINSON’S DISEASE AND OTHER RELATED DISEASES

4.2.2 GROWING GERIATRIC POPULATION

4.2.3 INCREASING INVESTMENT IN R&D

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY REQUIREMENTS

4.4 OPPORTUNITIES

4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS

5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS

5.3.4 IMPACT ON ELECTIVE PROCEDURE

5.3.5 IMPACT ON SUPPLY CHAIN

6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE

6.1 OVERVIEW

6.2 ORAL DOPAMINERGIC MEDICATION

6.3 WEARABLE AND WALKING AID DEVICES

6.4 DEEP BRAIN STIMULATION

6.5 OTHERS

7 GLOBAL FREEZE OF GAIT MARKET, BY END USER

7.1 OVERVIEW

7.2 HOSPITALS

7.3 CLINICS

7.4 OTHERS

8 GLOBAL FREEZE OF GAIT MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 US

8.1.2 CANADA

8.2 EUROPE

8.2.1 GERMANY

8.2.2 FRANCE

8.2.3 UK

8.2.4 ITALY

8.2.5 SPAIN

8.2.6 REST OF EUROPE

8.3 ASIA-PACIFIC

8.3.1 CHINA

8.3.2 INDIA

8.3.3 JAPAN

8.3.4 AUSTRALIA

8.3.5 SOUTH KOREA

8.3.6 REST OF ASIA-PACIFIC

8.4 REST OF THE WORLD

8.4.1 MIDDLE EAST

8.4.2 AFRICA

8.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET

9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.5.1 PARTNERSHIP & COLLABORATIONS

9.6 MAJOR PLAYERS SALES ANALYSIS

9.6.1 SALES & OPERATING INCOME

9.7 MAJOR PLAYERS R&D ANALYSIS

10 COMPANY PROFILES

10.1 VIATRIS INC.

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 GONDOLA MEDICAL TECHNOLOGIES SA

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 USTEP

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 GYENNO TECHNOLOGIES CO., LTD.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 MEDEXO ROBOTICS

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL ANALYSIS

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SUN PHARMACEUTICAL INDUSTRIES LTD

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 WALK WITH PATH

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 BEATS MEDICAL LIMITED

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 AGILITAS

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019–2030 (USD MILLION)

TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019–2030 (USD MILLION)

TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2030 (USD MILLION)

TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019–2030 (USD MILLION)

TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019–2030 (USD MILLION)

TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION)

TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019–2030 (USD MILLION)

TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION)

TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION)

TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION)

TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET

TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET

TABLE 65 PARTNERSHIP & COLLABORATIONS

TABLE 66 VIATRIS INC.: PRODUCTS OFFERED

TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED

TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS

TABLE 69 USTEP: PRODUCTS OFFERED

TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED

TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED

TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED

TABLE 74 WALK WITH PATH: PRODUCTS OFFERED

TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED

TABLE 76 AGILITAS: PRODUCTS OFFERED

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Market Research Future社の医療分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Market Research Future社はどのような調査会社ですか?


マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。   下記分野については、分野毎に専... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る